Clinical Trial Development for Biosimilars

Main Article Content

Juthamas Pispingkam
Wittawat Viriyabacha

Downloads

Download data is not yet available.

Article Details

Section
Review Article
Author Biographies

Juthamas Pispingkam, Medicines Regulation Division, Food and Drug Administration, Nonthaburi, Thailand

Medicines Regulation Division, Food and Drug Administration, Tiwanon Road, Muang District, Nonthaburi, 11000, Thailand

Wittawat Viriyabacha, Medicines Regulation Division, Food and Drug Administration

Medicines Regulation Division, Food and Drug Administration, Tiwanon Road, Muang District, Nonthaburi, 11000

References

1. Derbyshire M. Patent expiry dates for biologicals. GaBI 2017;7(1):29-34. doi: 10.5639/gabij.2018.0701.007.


2. Sanjeev KG, Chaudhari PS, Rajalaxmi N. Opportunities and challenges in biosimilar development [internet]. Burlington MA: BioProcess International; 2017 [cited 2019 May 6] .Avialable from: https://bioprocessintl.com/manufacturing/biosimilars/opportunities-challenges-biosimilar-development/


3. Verbeeck RK. Bioequivalence, therapeutic equivalence and generic drugs. Acta Clinica Belgica 2009;64(5):379-383. doi: 10.1179/acb.2009.063.


4. Dranitsaris G, Dorward K, Hatzimichael E, Amir E. Clinical trial design in biosimilar drug development. Investigational New Drugs 2012;31(2):479-487. doi: 10.1007/s10637-012-9899-2.


5. Perks B. Supporting biosimilarity and extrapolation. Generics and Biosimilars Initiative 2015;4(4):180-183. doi: 10.5639/gabij.2015.0404.041.


6. U.S. Food and Drug Administration. Biosimilar development, review, and approval: Can a biosimilar be approved for an indication that is approved for the reference product even if the biosimilar is not directly studied in that indication? [Internet]. U.S FDA; 2015. [cited 2019 May 6]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval#indication


7. U.S. Food and Drug Administration. Guidance document: Scientific considerations in demonstrating biosimilarity to a reference product [Internet]. U.S FDA; 2015. [cited 2019 May 6]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf


8. World Health Organization. Guidelines on evaluation of similar biotherapeutic product (SBPs) [Internet]. WHO; 2009. [cited 2019 May 6].Available from: https://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf


9. Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics: targets & therapy 2017;11:5–11. doi: 10.2147/BTT.S124476.


10. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood 2014;124(22):3191-3196. doi: 10.1182/blood-2014-06-583617.